For pharmaceutical manufacturers, the question is whether a specific formulation can perform consistently under continuous conditions. That requires evidence on material behaviour, process interactions and the sources of variability that can affect the state of control.
This is the challenge addressed by DFE Pharma’s Continuous Manufacturing platform. This platform brings together excipients characterised for continuous processes, access to a representative non-GMP testing environment and multidisciplinary formulation and process expertise to support decisions from feasibility through optimisation and lifecycle management.
Why confidence matters in CM adoption
A continuous processing line links unit operations more closely than a conventional batch process. ICH Q13 notes that changes in one part of an integrated CM system may affect upstream or downstream operations. This places particular emphasis on understanding relationships between material attributes, process parameters and product quality.
Powder flow, bulk density, particle-size distribution, feeding behaviour and blend uniformity can all influence process performance. Their relevance depends on the equipment configuration, formulation composition and operating range. A formulation that performs adequately in a batch process therefore cannot be assumed to translate directly to CM without evaluation.
The development question also varies depending on the manufacturer. A pharmaceutical company considering CM may first need to establish technical feasibility before committing to equipment or a development route. A company with established capabilities may be focusing on improving throughput, robustness or understanding of raw-material variability. In both cases, confidence is built through structured experimentation and interpretation rather than equipment selection alone.
Excipients designed for continuous processing
Material selection is one of the earliest and most important decisions in CM development. Excipients must support stable feeding, reproducible processing and robust performance over time. Variability that may be manageable in batch production can become more visible in continuous systems.
DFE Pharma offers a differentiated excipient portfolio characterized to support continuous manufacturing processes. The objective is not to treat an excipient as universally ‘CM-ready’, but to determine whether its material attributes and functional performance are appropriate for the intended formulation and process. This becomes particularly important when variability is considered. Continuous systems can make changes in material behaviour visible over a shorter time scale than batch manufacturing. Understanding excipient consistency, critical material attributes and excipient–process interactions can therefore support formulation design, process development and control strategy definition.
Learning before investing
A common barrier to CM adoption is access to an environment where formulations and process assumptions can be tested without interfering with commercial GMP operations. Building dedicated infrastructure for exploratory work may also be difficult to justify before technical feasibility is established.
As part of its CM platform, DFE Pharma has added continuous manufacturing capabilities to its Closer to the Formulator (C2F) Center of Excellence in Hyderabad, India. The setup features a Gericke Formulation Skid with modular feeding and blending options in a non-GMP environment, enabling rapid iteration and practical assessment without disrupting existing GMP manufacturing or requiring upfront infrastructure investment.
Depending on the objective, evaluations can focus on feeding performance, formulation behaviour, process settings or interactions between material properties and downstream processing. The wider C2F infrastructure also provides access to pre-blending, tableting and analytical capabilities.
The value lies in generating evidence that supports a decision: identifying formulations that warrant further development, clarifying where additional investigation is needed and reducing assumptions carried into technology transfer or commercial production.
Turning CM data into decisions
CM development generates complex data, but its value depends on how effectively that information is interpreted and applied.
DFE Pharma’s CM platform brings together expertise in formulation development, process understanding, analytics and variability science, complemented by Gericke’s experience in continuous feeding and blending technology. This combined perspective can be applied to formulation refinement, process-window definition, variability assessment and interpretation of development data.
The approach also reflects the lifecycle perspective described in ICH Q13, which addresses the development, implementation, operation and lifecycle management of CM. Regulatory readiness is therefore closely linked to process understanding: the rationale for material selection, operating ranges and control measures needs to be supported by development evidence.
Moving forward with confidence
As CM adoption advances, the companies best placed to benefit will be those that connect material performance, process understanding and regulatory thinking early in development.
DFE Pharma’s Continuous Manufacturing platform is built around those needs. By integrating CM-ready excipients, representative testing environment and applied scientific expertise, it helps manufacturers reduce uncertainty and make better decisions at every stage of their CM journey.
Pharmaceutical manufacturers exploring Continuous Manufacturing or looking to further optimize an established CM process can meet DFE Pharma’s experts at CPHI Milan 2026, booth 1A34 in Hall 1, to discuss formulation challenges, process performance and the next steps in development and learn how the platform can support confident development decisions. To learn more, explore DFE Pharma’s Continuous Manufacturing platform here or contact the company.
